Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study Meeting Abstract
| Authors: | Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; Van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C. S.; Bhagia, P.; Rha, S. Y. |
| Abstract Title: | Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S851 |
| End Page: | S852 |
| Language: | English |
| ACCESSION: | WOS:001087480202185 |
| DOI: | 10.1016/j.annonc.2023.09.1424 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1511O -- Source: Wos |
